ClinicalTrials.gg
CompletedNCT02183129Updated Nov 24, 2023

Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee

A Phase 4 interventional study of Diclofenac and Meloxicam in Osteoarthritis, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 15 years 3 months after the study started (first participant enrolled Apr 1999, registered Jul 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Osteoarthritis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Boehringer Ingelheim.

Started
1999
the only one that year
Phase 4
3 of 15
none open now
Registered
8th of 15
by date

Among the 15 studies in Osteoarthritis by Boehringer Ingelheim, this one is the only one that started in 1999, is one of 3 in phase 4, and was the 8th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies in Osteoarthritis by Boehringer Ingelheim is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Osteoarthritis by Boehringer Ingelheim as a file.
02

Study summary

To assess the efficacy and safety of meloxicam 7.5mg once daily compared with diclofenac 100mg SR once daily over a treatment period of 8 weeks

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritis of the knee requiring the therapy with non-steroidal anti-inflammatory drugs (NSAIDs)

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Meloxicam

    Drug: Meloxicam

  • Active comparator
    Diclofenac

    Drug: Diclofenac

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in pain on active movement assessed by a 100 mm visual analogue Scale (VAS)

    Time frame: Baseline, 8 weeks after first drug administration

Secondary outcomes

  1. Change from baseline in Lequesne index

    Time frame: Baseline, 8 weeks after first drug administration

  2. Change from baseline in global assessment by the patient and doctor on a 3-point scale

    Time frame: Baseline, 8 weeks after first drug administration

  3. Number of patients with significant changes from baseline in Laboratory values

    Time frame: Baseline, 8 weeks after first drug administration

  4. Number of patients with significant changes from baseline in physical examinations

    Time frame: Baseline, 8 weeks after first drug administration

  5. Number of patients with Adverse Events

    Time frame: Up to 8 weeks after first drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 1999 to primary completion in Nov 1999, 7 months.

Of 63 phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 60. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
StartActual
Apr 1, 1999
Primary completionActual
Nov 1, 1999
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183129
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Apr 1, 1999
Primary completion
Nov 1, 1999
Last update
Nov 24, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion